Spain· ES:1221631001
BREYANZI 1,1-70 × 10E6 CELULAS/ML / 1,1-70 × 10E6 CELULAS/ML DISPERSION PARA PERFUSION
A medicinal product containing lisocabtagén maraleucel, registered in Spain by Bristol-Myers Squibb Pharma Eeig.
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- lisocabtagén maraleucel
- Manufacturer
- Bristol-Myers Squibb Pharma Eeig
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lisocabtagén maraleucel in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsBreyanzi >= 5.1 x 10^6 cellen [CD4 component], suspensie voor injectieCelgene Europe B.V.
- CanadaBREYANZIBRISTOL-MYERS SQUIBB CANADA
- CzechiaBREYANZIBristol-Myers Squibb Pharma EEIG, Dublin
- FinlandBreyanziBristol-Myers Squibb Pharma EEIG
- FranceBREYANZI 1,1 à 70 × 1 000 000 cellules/ml / 1,1 à 70 × 1 000 000 cellules/ml, dispersion pour perfusionBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- United KingdomBreyanzi 1.1million-70million cells/ml / 1.1million-70million cells/ml dispersion for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandBreyanzi 1.1-70 x 10^6 cells/mL/1.1-70 x 10^6 cells/mL dispersion for infusionCelgene Europe B.V.
- IcelandBreyanziBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Breyanzi
- Liechtenstein · Breyanzi
- Norway · Breyanzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/026fa3be-3e05-40d5-bed0-8d8f0b216bca GET /v1/drugs/026fa3be-3e05-40d5-bed0-8d8f0b216bca?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Uso Hospitalario",
"estado": "{\"aut\":1746695352000}",
"nregistro": "1221631001",
"substance": "lisocabtagén maraleucel"
}See everything about lisocabtagén maraleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.